{"id":"NCT02091414","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.","officialTitle":"An Open Label Study to Evaluate the Effect of CellCept in Combination With Cyclosporine A and Steroids on Renal Function and the Prevention of Acute Rejection in Heart Transplant Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2014-03-19","resultsPosted":"2014-10-29","lastUpdate":"2014-10-29"},"enrollment":36,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Heart Transplantation"],"interventions":[{"type":"DRUG","name":"mycophenolate mofetil (MMF)","otherNames":["CellCept"]},{"type":"DRUG","name":"cyclosporine A (CsA)","otherNames":[]},{"type":"DRUG","name":"corticosteroids","otherNames":[]}],"arms":[{"label":"MMF, CsA, Corticosteroids","type":"EXPERIMENTAL"}],"summary":"This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant. The anticipated time on study treatment is 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week","timeFrame":"Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24","effectByArm":[{"arm":"MMF + CsA","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":3,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":["Cough","Elevated blood sugar","Hyperglycemia","Tachycardia","Hypertension"]}}